In Vivo and In Vitro Studies on Virulence and Host Responses to Saccharomyces cerevisiae Clinical and Non-Clinical Isolates

Abstract

We have studied the virulence and host responses to several clinical and non-clinical Saccharomyces cerevisiae isolates: two vaginal isolates (60, 61), one isolate from faeces (20), a brewer's yeast isolate used in dietetics (D14), one S. boulardii isolate from a commercial probiotic product, and a reference natural wine yeast (CECT 10431). Hematogenously disseminated infection in a mouse model demonstrated that four isolates (all, except 20 and 10431) were able to colonize preferentially the brain, as well as kidney and spleen, to a lesser extent, of immunocompetent mice. In vitro adhesion assays to epithelial and endothelial cell lines also showed an increased adherence ability of strains 60, 61, D14 and S. boulardii. In vitro cytokine production assays by RAW 264.7 murine macrophages challenged with yeasts showed a relative increased production of TNF- in response to the 20 and 10431 strains; viability of RAW cells after coculture was similar in all cases (2-5% non-viable cells) except for 60 strain (11% non-viable cells). In vitro phagocytosis assays of yeasts by RAW cells showed that two isolates (D14 and particularly S. boulardii) were engulfed less efficiently. These results point out that S. cerevisiae isolates, from both clinical and non-clinical (dietetic and probiotic) origin, may vary in the expression of putative virulence factors contributing to their ability to develop the infectious process.